Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Novel Agents, Combos Excite in Multiple Myeloma

Angelica Welch
Published: Tuesday, Nov 28, 2017

Dr. Dan T. Vogl

Dan T. Vogl, MD
Researchers are continuing to build on recent success in the field of multiple myeloma, says Dan T. Vogl, MD.

on Hematologic Malignancies, Vogl, director, Abramson Cancer Center Clinical Research Unit, assistant professor of medicine at the Hospital of the University of Pennsylvania, discussed some of these novel agents alone and in combination. He also highlighted the potential with CAR T-cell therapy in the multiple myeloma paradigm.

OncLive: Please provide an overview of your presentation.

Vogl: This is an exciting time to treat patients with multiple myeloma because, in addition to all of the great [therapies] that are already approved for treatment, there are some new options that allow us to keep treating patients for many lines of therapy—and we are getting good responses. One of our newer agents, daratumumab, is being increasingly used in earlier lines of therapy and can now be used in combination with pomalidomide (Pomalyst). I also discussed the upcoming introduction of subcutaneous formulation of daratumumab that will make the infusions a lot shorter for our patients, and make the treatment a lot more convenient. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication